Hence, in contrast to the prediction of treatment responses to HER2-targeted mAb therapy in breast cancer [13], EGFR protein expression analysis or its regulation at the DNA level are not in the focus of treatment prediction of response to EGFR-targeted therapy in CRC patients. This evidence concerns the gene ERBB2 and breast carcinoma.